首页> 外文期刊>Infection and immunity >Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity.
【24h】

Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity.

机译:具有脂多糖抑制活性的兔阳离子蛋白(CAP18)的表征。

获取原文
           

摘要

Cationic antibacterial proteins (CAP) were purified from rabbit granulocytes, and the effects of CAP on lipopolysaccharide (LPS)-induced tissue factor generation by murine peritoneal macrophages and human blood monocytes were studied. CAP were purified from rabbit peritoneal leukocytes by using as an assay the agglutination of erythrocytes coated with Re-LPS. Two proteins with CAP activity, CAP18 (18 kDa) and CAP7 (7 kDa), were isolated by acid extraction, ethanol precipitation, affinity chromatography, gel filtration, and reverse-phase high-pressure liquid chromatography. On the basis of protein sequencing, CAP7 was identified as the C-terminal fragment of CAP18, designated CAP18(106-142). Various forms of LPS (S-LPS, Re-LPS, and lipid A) activate murine macrophages and human blood monocytes to generate tissue factor (tissue thromboplastin). Incubation of LPS for 18 h with partially purified CAP (heparin-Sepharose fraction) inhibited the capacity of LPS to induce tissue factor; however, purified CAP18 inhibited about 75% of the activity of S-LPS after 1 h of incubation. CAP more effectively inhibited S-LPS than Re-LPS or lipid A. Synthetic CAP18(106-142) inhibited LPS-induced tissue factor generation by murine macrophages. CAP18(106-142) has greater LPS-binding and LPS-neutralizing activities than CAP18. We hypothesize that CAP18 and the derivative peptide, CAP18(106-142), bind to LPS and alter the capacity of LPS to initiate disseminated intravascular coagulation. In this regard, CAP may have therapeutic potential for sepsis and endotoxin shock.
机译:从兔粒细胞中纯化出阳离子抗菌蛋白(CAP),研究了CAP对鼠腹膜巨噬细胞和人血单核细胞对脂多糖(LPS)诱导的组织因子生成的影响。通过使用包被Re-LPS的红细胞的凝集作为测定法从兔腹膜白细胞中纯化CAP。通过酸提取,乙醇沉淀,亲和色谱,凝胶过滤和反相高压液相色谱分离出两个具有CAP活性的蛋白CAP18(18 kDa)和CAP7(7 kDa)。根据蛋白质测序,将CAP7鉴定为CAP18的C末端片段,命名为CAP18(106-142)。各种形式的LPS(S-LPS,Re-LPS和脂质A)激活鼠巨噬细胞和人血单核细胞以产生组织因子(组织凝血活酶)。用部分纯化的CAP(肝素-琼脂糖部分)孵育LPS 18 h会抑制LPS诱导组织因子的能力。然而,孵育1小时后,纯化的CAP18抑制了S-LPS活性的约75%。 CAP比Re-LPS或脂质A更有效地抑制S-LPS。合成CAP18(106-142)抑制LPS诱导的鼠巨噬细胞组织因子的产生。 CAP18(106-142)比CAP18具有更大的LPS结合和LPS中和活性。我们假设CAP18及其衍生肽CAP18(106-142)与LPS结合并改变LPS启动弥散性血管内凝血的能力。在这方面,CAP可能具有败血症和内毒素休克的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号